Linking dioxins to diabetes: epidemiology and biologic plausibility. by Remillard, Rene B J & Bunce, Nigel J
Environmental Health Perspectives • VOLUME 110 | NUMBER 9 | September 2002 853
Linking Dioxins to Diabetes: Epidemiology and Biologic Plausibility
Rene B. J. Remillard and Nigel J. Bunce
Toxicology Program, University of Guelph, Guelph, Ontario, Canada 
The term dioxin can refer both speciﬁcally to
2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) and more generally to other
polychlorodibenzo-p-dioxin congeners, poly-
chlorinated dibenzofurans, and coplanar
polychlorinated biphenyls. Like other
organochlorine compounds, dioxin-like com-
pounds (DLCs) are persistent, lipophilic, and
prone to bioaccumulation. Most toxicologic
work has been carried out with TCDD, and
the toxicologic behavior of other DLCs is
usually assumed to be similar. The total
dioxin concentration is estimated as its toxic
equivalence (TEQ), where TEQ = Σ(DLC)i
× (TEF)i and the TEFs are toxic equivalency
factors that normalize the toxic potencies of
the various DLCs to that of the reference
toxicant TCDD, with TEF = 1 (1).
When the toxicity of TCDD was ﬁrst dis-
covered, attention was directed toward its
acutely lethal effects (2–4) in highly sensitive
rodents such as guinea pigs (5). The realiza-
tion that human beings are less susceptible to
these acute effects shifted the focus to low-
level chronic effects such as carcinogenicity
(6) and reproductive toxicity (7,8), both of
which can be induced in animal models at
concentrations close to those to which
humans are exposed (9). 
Humans are exposed to DLCs either occu-
pationally or environmentally. Environmental
sources of DLCs include combustion by-prod-
ucts that form whenever organic materials are
burned in the presence of chlorine sources and,
in the case of coplanar PCBs, improper dis-
posal and accidental contamination (9).
Occupations that formerly led to exposure
included the manufacture and use of 2,4,5-
trichlorophenol and associated products such
as herbicides, and bleaching of wood pulp
with chlorine (10,11). Releases of dioxins
from these activities have greatly declined
(12). In the general population, exposure
comes mostly from fatty foods such as meat,
fish, and dairy products, at the rate of some
3–6 pg of TEQ/kg body weight/day (9).
Almost all human subjects have detectable
body burdens of DLCs, mostly stored in adi-
pose tissue, and because DLCs have long
whole-body half-lives, levels in the general
population have probably not yet kept pace
with lower rates of release to the environment.
Low levels of dioxin exposure have
recently become a focus of interest in the con-
text of their possible link with the incidence of
diabetes. Adult-onset diabetes (13,14), whose
incidence continues to rise in Western coun-
tries, is a metabolic disorder involving abnor-
mal energy metabolism (15,16). Perhaps
signiﬁcantly, lethal poisoning by dioxins also
involves disruption of energy metabolism,
characterized by depletion of lipid stores of
the affected animal (the “wasting syndrome”)
(17). In rats, Rozman (18) demonstrated
nearly identical dose–response behavior by
TCDD for suppression of food intake and
inhibition of the enzyme phosphoenolpyru-
vate carboxykinase (PEPCK) involved in glu-
coneogenesis [although later work (19) with a
wider range of rodents did not consistently
afﬁrm this correlation]. Experimental evidence
has also linked dioxin exposure to impaired
glucose transport, leading to speculation that
chronic low-level exposure to dioxins might
be a risk factor for diabetes. In this article, we
review the relevant epidemiologic studies con-
cerning the strength of association between
DLCs and adult-onset type 2 diabetes 
[non-insulin-dependent diabetes mellitus
(NIDDM)] and consider mechanisms that
attempt to provide biologic plausibility for
this association. The focus is on biochemical
similarities and differences among aryl hydro-
carbon (Ah) receptor function, mechanisms
for diabetogenesis, and peroxisome prolifera-
tor-activated receptor (PPAR) functions.
Review of Epidemiologic
Studies
Several epidemiologic studies have linked
high dioxin burdens to increased risk of dia-
betes or modified glucose metabolism
(20–25). The following groups of exposed
humans have been the subject of dioxin-
related epidemiologic studies: German
employees of factories where phenoxy herbi-
cides were manufactured (20); U.S. employ-
ees of factories located in Newark, New
Jersey, and Verona, Missouri, involved in the
manufacture of 2,4,5-trichlorophenol and the
associated herbicide 2,4,5-trichlorophenoxy-
acetic acid (2,4,5-T, no longer used in
Europe or North America) (21,22); residents
of Seveso, Italy, where a 1976 explosion at a
2,4,5-trichlorophenol factory exposed local
residents to TCDD (23); and U.S. Air Force
veterans involved in spraying defoliants dur-
ing the Vietnam War (24–27). 
A major difficulty is that exposure
occurred many years before the epidemio-
logic studies. Dioxin levels at the time of
exposure must be back-calculated from cur-
rent concentrations in serum lipids, using the
whole-body half-life of TCDD, which is
quite variable in humans, 5.8–9.6 years (27).
This variation probably reﬂects differences in
body fat, with high body fat acting to retain
TCDD, because mobilization from adipose
tissue may be the rate-limiting step in its
elimination (28,29). Moreover, although the
study subjects were all exposed speciﬁcally to
TCDD (a ubiquitous contaminant in 2,4,5-
trichlorophenol and 2,4,5-T), they were also
exposed to much larger amounts of phenols
and phenoxy herbicides, and both they and
the referents were also exposed to other
DLCs. With one exception, the epidemio-
logic studies monitored only the TCDD
concentrations.
Sweeney et al. (21) compared 281 living
male U.S. workers, employed more than 15
years earlier in the production of chemicals
contaminated with TCDD, with an unex-
posed group of 260 volunteers. The workers
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pg TCDD/g lipid ppt); that of the referents
was 7 ppt. Exceptionally, these investigators
measured serum lipid concentrations of other
DLCs, which were similar in both workers
and controls. The TEQ values for workers
and referents, based on 1998 values of TEFs
(1), were 256 and 35 ppt; that is, the ratio of
exposed to unexposed concentrations fell
from 31 based on TCDD alone to 7.3 based
on TEQ. Sweeney et al. (21) found a slight
increase in the risk of diabetes [odds ratio
(OR) = 1.12, p < 0.003] and high fasting
serum glucose (p < 0.001) with increasing
serum concentrations of TCDD, but cau-
tioned that age, weight, and family history are
more important risk factors than TCDD
exposure in the development of diabetes.
Serum triglyceride levels increased with
TCDD exposure, and testosterone levels were
lower in the exposed group.
A follow-up study of the same cohort, but
excluding individuals under treatment for
diabetes, considered the OR for diabetes as a
function of serum lipid TCDD concentration
(22). When all subjects were included, irre-
spective of TCDD level, the OR for diabetes
was 1.49 [95% confidence limit (CL),
0.77–2.91). However, no dose–response rela-
tionship was seen between (present) TCDD
levels of the exposed workers and either dia-
betes incidence (Table 1) or mean glucose
levels.
Somewhat parallel results were reported
by Zober et al. (20) in the follow-up of work-
ers exposed to TCDD in a 1953 accident in
Germany. Development of chloracne was
used as a surrogate for TCDD exposure at the
time of the accident. As an exception, work-
ers experiencing chloracne had a lower inci-
dence of diabetes than did referents, as
defined by the International Classification of
Diseases, 9th revision (30). This inverse rela-
tionship was strongest for workers with the
least chloracne. We discuss this study again
further below.
Henriksen et al. (24) studied glucose lev-
els, insulin levels, and diabetes prevalence in
989 U.S. veterans of Operation Ranch Hand
who were exposed to Agent Orange in
Vietnam. The referents were 1,276 other
U.S. veterans who served in Southeast Asia
during that period, but who were not
involved with the defoliant program.
Veterans with a history of diabetes before ser-
vice were excluded from the study. An impor-
tant difference from the studies of industrial
workers discussed above is the much lower
serum lipid concentrations of TCDD: mean
values 12.2 ppt for Ranch Hand veterans and
4 ppt for referents at the time of study in
1992. Ranch Hand veterans had a higher
incidence of serum glucose abnormalities [rel-
ative risk (RR), 1.4; 95% CL, 1.1–1.8],
serum insulin abnormalities (RR, 3.4; 95%
CL, 1.9–6.1), diabetes (RR, 1.5; 95% CL,
1.2–2.0), and the use of oral medications to
control diabetes (RR, 2.3; 95% CL, 1.3–3.9).
The Ranch Hand subjects were divided into
three exposure groups: background (BG)
with TCDD < 10 ppt in 1992, LO (extrapo-
lated initial TCDD < 94 ppt), and HI
(extrapolated initial TCDD > 94 ppt; Table
2). High TCDD concentrations correlated
with increasing body fat and shorter time to
onset of diabetes among diabetic veterans.
Michalek et al. (25) used the same deﬁni-
tions for the BG, LO, and HI exposure
groups in a similar study of 871 Ranch Hand
veterans and 1,121 referent Vietnam veterans.
Table 3 shows abnormalities in the HI group
for insulin levels (diabetic and nondiabetic
subjects), fasting glucose concentrations (dia-
betics), and steroid hormone-binding globu-
lin (SHBG) among diabetics.
Longnecker and Michalek (26) investi-
gated whether the effects of prior exposure to
TCDD persist even after levels returned to
background, by restricting their investigation
to Ranch Hand veterans in the BG group.
Again, there was a relation between increased
body mass index and higher serum lipid
TCDD. Quartiles were established, and Q1
was deﬁned as the reference group (Table 4).
Although not all statistically signiﬁcant, dia-
betes incidence and changes in serum insulin
and blood glucose all showed a dose–response
trend with increasing serum lipid TCDD.
Cranmer et al. (31) examined 69 people
who lived within 25 miles of the Vertac/
Hercules Superfund site in Jacksonville,
Arkansas, restricting their study to those with
normal glucose levels during glucose tolerance
testing. Only subjects in the top decile for
serum lipid TCDD concentration showed
any statistically signiﬁcant effects. Hence, the
reference group was TCDD < 15 ppt (n =
62), and the high exposure group was TCDD
> 15 ppt (n = 7). No differences between the
groups were seen for blood glucose, after
either fasting or a 75-g glucose challenge, but
differences in insulin levels were observed
(Table 5). Other known risk factors for
hyperinsulinemia could not explain this ﬁnd-
ing, thus suggesting that high blood TCDD
concentrations may cause insulin resistance.
A well-studied population is that of
Seveso, Italy, where a 1976 explosion at a fac-
tory that produced 2,4,5-trichlorophenol
exposed the general populace to TCDD.
Bertazzi et al. (23) reported death rates
among this population to 1991 in three zones
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Table 1. Lack of dose–response relationship between present TCDD levels of the exposed workers and
diabetes incidence. 
TCDD (ppt) < 20 20–75 75–238 > 238
OR (95% CL) 2.11 (0.77–5.75)  1.51 (0.53–4.27)  0.67 (0.17–2.57) 1.97 (0.79–4.90)
Diabetes deﬁned as > 7.8 mmol/L glucose on 2 consecutive days after a 12-hr fast. Results were unchanged when reeval-
uated at 7.0 mmol/L glucose. Hyperglycemia = fasting serum glucose > 140 mg/dL. The same criteria were also used in
Sweeney et al. (21). Data from Calvert et al. (22).
Table 2. Dose–response relationships between serum lipid TCDD and glucose metabolism parameters for
Ranch Hand subjects. 
Condition BG [OR (95% CL)]  LO [OR (95% CL)]  HI [OR (95% CL)]
Diabetes 0.7 (0.5–1.0) 1.3 (1.0–1.7) 1.5 (1.2–2.0)
Fasting glucose  0.7 (0.5–1.0) 1.3 (0.9–1.7) 1.2 (0.9–1.7)
2 hr postglucose  0.9 (0.6–1.2) 1.2 (0.9–1.7) 1.6 (1.2–2.2)
High insulina 0.8 (0.4–1.9) 1.0 (0.4–2.5) 3.4 (1.9–6.1)
Diabetes is deﬁned as > 200 mg/dL 2 hr postprandial (or by medical diagnosis); hyperinsulemia is deﬁned as serum insulin
> 97th percentile of comparison group; for hyperglycemia, fasting glucose challenged with 100 g glucose measured 2 hr
postprandial (> 115 mg/dL = high; 140–200 mg/dL = impaired; > 200 mg/dL = abnormal). Subjects were divided into three
groups: background (BG: TCDD < 10 ppt in 1992), LO (extrapolated initial TCDD < 94 ppt) and HI (extrapolated initial TCDD >
94 ppt), exposure groups. Data from Henricksen et al. (24).
aAmong nondiabetics.
Table 3. Abnormalities in the HI group for insulin levels (diabetic and nondiabetic subjects), fasting glu-
cose concentrations (diabetics) and SHBG among diabetics for 871 Ranch Hand veterans and 1,121 refer-
ent Vietnam veterans (means). 
Condition Referents BG LO HI
Body fat (%) 21.7 20.1 22.4 23.4
Insulin, nondiabetic (µIU/mL) 67.7 62.6 64.2 81.1
Insulin, diabetic (µIU/mL) 63.6 72.9 87.3 48.5
Fasting glucose, nondiabetic (mg/dL) 99.0 99.3 98.9 98.6
Fasting glucose, diabetic (mg/dL) 137.4 132.2 126.7 156.1
SHBG, nondiabetic (nmol/L) 28.5 29.9 31.4 30.0
SHBG, diabetic (nmol/L) 24.0 24.6 24.3 31.7
Exposure groups: BG, background (TCDD < 10 ppt in 1992); LO, extrapolated initial TCDD < 94 ppt; HI, extrapolated initial
TCDD > 94 ppt. Diabetes is defined as > 200 mg/dL postprandial or by medical diagnosis; hyperinsulemia and hyper-
glycemia, by statistical comparison with referents. Data from Michalek et al. (25).(labeled in decreasing order of exposure as A,
B, and R) compared with the background
Italian population. For both males and
females, overall death rates were within Italian
norms, but there were consistent slight
increases in diabetes mortality among the
exposed populations (Table 6). Unfortunately,
no data on diabetes incidence were provided.
All RRs are clearly small but point consis-
tently in the direction of a slight enhancement
of mortality from diabetes with dioxin expo-
sure, especially for females.
Discussion of Epidemiologic
Studies
Except for the chemical manufacturing work-
ers (20,22), there is a rather consistent ﬁnd-
ing of a slight increase in diabetes incidence
among subjects exhibiting elevated serum
lipid TCDD concentrations, as well as abnor-
mal glucose and/or insulin levels among sub-
jects who were exposed to TCDD. No
information is available to identify other sub-
stances to which the chemical manufacturing
workers may have been exposed, although
exposure to high levels of trichlorophenol
and phenoxy herbicides may be inferred.
Inevitably, there are differences in the statisti-
cal measures used in these studies, making
direct comparisons difﬁcult. Another possible
confounding factor is the choice of referents
(allegedly unexposed chemical workers rather
than the general populations).
Leaving aside the studies involving indus-
trial workers for the moment, several factors
suggest underestimation of the RR parame-
ters. First, and typical of studies involving
xenobiotics, no completely “dioxin-free” con-
trol population is available; there is back-
ground exposure of both subjects and
referents to TCDD; further, all subjects are
exposed to other DLCs, usually to an
unknown extent. This compresses the appar-
ent OR for an adverse effect of TCDD (but
by an unknown amount), just as if one com-
pared the RR of lung cancer between heavy
smokers and light smokers, rather than
between heavy smokers and nonsmokers. In
addition, present knowledge does not indi-
cate the significance of chronic exposure to
approximately 5 pg TCDD/g serum lipid (or
35 pg TEQ per gram of serum lipid) in the
general population.
Second, the actual serum lipid TCDD
concentrations at the time of exposure are
always unknown and must be extrapolated
back from the time of analysis, many years
later. This compresses the range of TCDD
levels between slightly and highly exposed
subjects, because all concentrations are lower;
also, one cannot be confident that the rank
ordering of TCDD concentrations at the time
of analysis matches the rank ordering at the
time of exposure, because whole-body half-
lives are variable. One cannot improve the sta-
tistical power of these studies by recruiting
additional subjects, because all those willing to
participate are already involved (20).
The justification for the study by
Longnecker and Michalek (26) was the possi-
bility (23,32,33) that prior dioxin exposure
may have health consequences after dioxin
levels have returned to the background range.
The investigators found a slight correlation
between diabetes incidence and serum lipid
TCDD among Ranch Hand veterans whose
TCDD concentrations had returned to the
normal range by the time of the study,
although the data did not necessarily indicate
a causal relationship.
Biologic Plausibility between
DLCs and Diabetes: Receptor-
Mediated Mechanisms
DLCs are universally regarded as exerting
their toxic effects through binding with the
Ah receptor, a cytoplasmic multimeric pro-
tein complex whose structure and function
were reviewed recently (34). The Ah receptor
ligand-binding subunit, often abbreviated
ALBS, is a ligand-activated transcription fac-
tor, whose identiﬁed heterodimerization part-
ners include Arnt (34), the NFκB protein
RelA (35), and retinoblastoma protein (36).
ALBS/Arnt heterodimers also bind coregula-
tors that influence the activity of various
nuclear receptors, such as the estrogen recep-
tor (37,38). Although the Ah receptor is
believed to mediate all of the toxic effects of
DLCs, the possibility exists that components
of the multiprotein complex besides ALBS
initiate some of the signaling pathways when
the liganded complex dissociates.
In the context of glucose metabolism,
PPARs, which are also nuclear receptors, are
ligand-activated transcription factors that
control lipid metabolism and homeostasis.
PPARs have recently been linked to cellular
proliferation, differentiation, and apoptosis,
as well as to obesity, diabetes, atherosclerosis,
inﬂammation, cancer, and aging (39). Among
PPAR coregulatory proteins, a number have
PPAR-binding LXXLL motifs in their pri-
mary sequences. The three transcription fac-
tors PPAR α, β (also called δ), and γ are
expressed from related genes with varying
degrees of homology and have isoforms that
are splice variants (40).
Links between PPARγ and diabetes are its
mediation of the antidiabetic effects of thia-
zolidinediones (see below) and the activated
receptor’s role in promoting differentiation of
adipocytes, which mediate glucose and lipid
homeostasis, and translation of the glucose
transporter protein GLUT4 (41,42). Because
DLCs inhibit preadipocyte differentiation
(43), Ah receptor activation may therefore
antagonize PPARγ function, perhaps suggest-
ing that dioxin exposure might be a risk fac-
tor for diabetes through antagonism of
PPARγ functions, which may lead to insulin
resistance. Enan et al. (44) and Liu and
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Table 4. Dose–response trend with increasing serum lipid TCDD for Ranch Hand veterans in the back-
ground group. 
Q1 Q2 Q3 Q4
TCDD in 1992, ppt < 2.8 2.8–4.0 4.0–5.2 > 5.2
Diabetes  0.93 (0.53–1.66) 2.51 (1.53–4.11)  2.63 (1.56–2.94)
Change in insulin (µIU/µL) 0.16 (0.02–0.30) 0.24 (0.09–0.38) 0.37 (0.23–0.51)
Change in fasting glucose (mg/dL) 1.3 (–0.3–2.8) 1.9 (0.3–3.4) 3.0 (1.5–4.6)
Change in postchallenge glucose (mg/dL) 4.8 (0.2–9.4) 6.2 (1.4–11) 10.2 (5.4–15)
Values are OR (95% CL). Diabetes, > 200 mg/dL postchallenge with 100 g glucose or medical diagnosis. Hyperglycemia
was not measured. The response to a glucose challenge was compared with those of the reference group. Data from
Longnecker and Michalek (26).
Table 5. Insulin levels, either fasting or after a 75-g glucose challenge, for residents living within 25 miles
of the Vertac/Hercules Superfund site in Jacksonville, Arkansas. 
Insulin level (mIU/mL)
TCDD > 15 ppt TCDD < 15 ppt OR for high insulin
Fasting 7.0 2.0 8.5
30 min postglucose 412 79 7.0
60 min postglucose 325 100 12
120 min postglucose 294 65 56
The reference group was TCDD < 15 ppt (n = 62) and the high-exposure group was TCDD > 15 ppt (n = 7). Subjects had
normal glucose tolerance in tests of 75 g glucose with blood sampled at 0, 30, 60, 120 min, with the amount of insulin
released, calculated in mIU/mL/hr, statistically greater than referents. Data from Cranmer et al. (31).
Table 6. Deaths to 1991 ascribed to diabetes among
residents of Seveso, Italy, who were exposed to
TCDD after a 1976 explosion at a 2,4,5-trichlorophenol
factory. 
No., RR (95% CL)
Zone Males Females
A None, NA 2, 1.8 (0.4–7.0)
B 6, 1.2 (0.5–2.7) 18, 1.8 (1.0–3.0)
R 38, 1.1 (0.8–1.5) 75, 1.2 (0.9–1.5)
The cause of death was obtained from death certiﬁcates.
Zones A, B, and R had decreasing exposure to TCDD. Data
from Bertazzi et al. (23).Matsumura (45) have shown that adipocytes
from dioxin-treated guinea pigs or mice
exhibit reduced glucose transport activity.
Consistent with antagonism of PPARγ func-
tions, Liu and Matsumura (45) found that
both the copy number of GLUT4 [which is
expressed in adipose and striated muscle tis-
sues (46)] and its mRNA were significantly
reduced in adipose tissue of mice after
TCDD treatment. This experiment involved
a single exposure at high dose and long expo-
sure time (116 mg/kg dioxin for 40 hr), in
contrast with human populations, which
experience years of exposure at much lower
doses; nevertheless, it raises the possibility
that dioxin exposure might lower GLUT4
expression in human subjects. Because the in
vivo concentration of any protein reﬂects the
balance between production and degradation,
continuous exposure to DLCs might gradu-
ally reduce the production of glucose trans-
porter proteins such as GLUT4, thereby
causing progressive insulin resistance. An
unknown factor, however, is how useful
rodent experiments are in modeling human
metabolism involving PPARs, because peroxi-
some proliferation is much more strongly
induced in rodents.
A novel class of insulin-sensitizing drugs,
thiazolidinediones (47), increases insulin-
stimulated glucose import rates in peripheral
tissues via increased expression of GLUT1
and GLUT4 (48). Thiazolidinediones bind
to and activate PPARγ in adipocytes, stimu-
lating the removal of glucose from the circu-
latory system and its transformation to lipids
(49). Suzuki et al. (50) evaluated the effects of
thiazolidinedione treatment on the expression
of 42 diabetes-related genes. If DLCs are
indeed diabetogens, their effect on the pro-
duction of these mRNAs should antagonize
that of thiazolidinediones, but this is not yet
known.
Thiazolidinediones also inhibit the action
of tumor necrosis factor α (TNF-α), a multi-
functional cytokine that induces insulin resis-
tance (47) and influences hyperlipidemia,
nutrient-sensing pathways, body fat, and mor-
tality after chronic infections. The TNF-α
system is thought to provide survival advan-
tage during periods of food shortage by
inducing peripheral insulin resistance, 
thus saving glucose for the brain (51).
Experiments carried out in the context of
dioxin-induced immunotoxicity (52–54) and
carcinogenesis (55) have revealed Ah recep-
tor-dependent increases in TNF-α expression
after TCDD exposure. A possible link to
adult-onset diabetes is that TNF-α has been
shown to reduce the production of PPARγ
mRNA [see Greene et al. (40) and references
therein], raising the possibility that chronic
dioxin-induced TNF-α expression might
cause adult-onset diabetes by inducing insulin
resistance.
Compared with other members of the
nuclear receptor superfamily, PPARs have a
spacious ligand-binding pocket (40) that
allows them to be activated by diverse ligands,
some of which, like DLCs, are polycyclic and
lipophilic. This suggests that certain ligands
for the Ah receptor might bind PPARγ and
interfere, positively or negatively, with its
activation. Such a finding might refute the
long-standing dogma that all the toxic effects
of DLCs are mediated by the Ah receptor,
although this idea has not yet been tested
experimentally. A potentially relevant obser-
vation is that TCDD-induced cytochrome
P450 (CYP)1A1 expression in the male
guinea pig is saturated at three orders of mag-
nitude lower than the amount of TCDD
required for acute lethality (16), which
demands different mechanisms for lethality
and CYP1A1 induction. One hypothesis
might have lethality involving DLC binding
to PPARs, and CYP1A1 expression involving
DLC binding to Ah receptor.
Another possible pathway for cross-talk
between Ah receptor and PPARγ signaling is
through LXXLL domains (nuclear receptor
boxes), which are present on numerous coac-
tivators and corepressors that bind to mem-
bers of the nuclear receptor superfamily
(56–63). Of these, SRC-1 was found to bind
Ah receptor via LXXLL motifs (64), whereas
RIP140 was shown to bind Ah receptor via
an LXXLL-independent mechanism (65).
Whereas these experiments explored the role of
LXXLL domains in coregulator sequences in
mediating binding to the Ah receptor, the pos-
sibility that ALBS contains LXXLL domains
that can bind to and inﬂuence the activity of
nuclear hormone receptors such as PPARγ has
never been determined. In that case, ALBS
might corepress PPAR transcription factors,
besides being a transcription factor itself.
The amino acid sequences of 10 Ah recep-
tors (zebraﬁsh, rabbit, chicken, human, mouse,
rat, two sequences from the killiﬁsh, and Ah
receptor A and B of the rainbow trout) were
downloaded from the Pubmed protein data-
base (66) and the Prosite Web site (67). They
were searched for LXXLL domains, including
those in which L is replaced by V, M or I,
which are chemically similar. The LXXLL
domains located at positions 48–52 and
114–118 of the rainbow trout Ah receptor A
sequence were conserved in all 10 sequences,
and the domain located at 441–446 was pre-
sent in 9 of the 10 sequences (Table 7). The
conservation of these sequences, especially the
one within the PAS domain, which mediates
heterodimerization, suggests that the Ah
receptor may bind receptors such as PPARγ,
although the small size of this consensus
sequence is also consistent with it having
arisen by chance.
Another link between Ah receptor and
PPAR functions is that both receptors inﬂuence
PEPCK activity or expression [PPARs (68–70)
and Ah receptor (17,71)]. Additionally, both
the Ah receptor and PPARα have been con-
nected to hyperlipidemia [Ah receptor (72) and
PPAR (73)], and type 2 diabetes is associated
with abnormal lipid metabolism (74). Another
analogy is that PPARγ is involved with the
action of interleukin-1 (IL-1), IL-6, and TNF-
α induction of IL-1β (40), whereas Ah receptor
functions inﬂuence or are inﬂuenced by IL-6
(75), IL-2 (76), and IL-1β (53,77).
As noted above, most of the extant epi-
demiologic studies involving highly exposed
industrially exposed workers do not follow
the pattern of a correlation between serum
lipid TCDD concentrations and diabetes-
related disorders (20,22). The workers were
involved speciﬁcally in the production of phe-
noxy herbicides: 2,4-dichlorophenoxyacetic
acid (2,4-D) and 2,4,5-T are known peroxi-
some proliferators that act by binding to
PPARs (78,79). Hence, we speculate that the
apparent lack of a positive association
between TCDD exposure and diabetes in the
industrial workers may have been caused by
antagonism between the diabetes-promoting
action of TCDD and the possible antidia-
betic actions of the phenoxy herbicides.
However, although Ah receptor function may
antagonize PPAR functions generally, its possi-
ble antagonism of PPARγ, which is implicated
in diabetes, has not been studied. Conversely,
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Table 7. Alignment of LXXLL and LXXLL-like domains in 10 Ah receptor primary amino acid sequences. 
Positions of conserved sequences
Species identiﬁers First Second Third
Rainbow trout (Oncorhynchus mykiss) Ahr A, AF065137a 48–51 LtgLL 114–118 LLqaL 441–446 (L)LgsL(M)
Rainbow trout (Oncorhynchus mykiss) Ahr B, T30557a 49–54 LtgLL 115–119 LLqaL 452–457 (L)LgsL(M)
Zebraﬁsh (Danio rerio) AF0634461.1a 48–52 LtnLL 122–126 LLqaL 450–455 (L)LgsM(L)
Rabbit (Oryctolagus cuniculus) D382261.1a 48–54 LasLL 117–121 LLqaL 454–459 (L)LsaL(M)
Chicken (Gallus gallus) AAF70373a 47–51 LasLL 117–121 LLqaL 454–459 (L)LsaM(L)
Homo sapiensb 49–54 LasLL 118–122 LLqaL 456–460 LLaaM
Mus speciesb 49–54 LasLL 116–120 LLqaL 450–454 (L)MsaL(I)
Rat speciesb 49–53 LasLL 116–120 LLqaL 454–459 (L)Msa(L)
Killiﬁsh (Fundulus heteroclitus) AF024591.2a 42–46 LasLL 108–113 LLqaL 448–453 (L)LgaL(M)
Killiﬁsh (Fundulus heteroclitus) AAC59a 49–53 LmeLL 113–118 LLqaL not present
Residues whose positions create an overlapping LXXLL domain are indicated in parentheses. 
aPubmed (66) sequences are identiﬁed with the ID number. bData from Prosite (67).although PPARγ is implicated in mediating
antidiabetic actions by thiazolidinediones,
possible contributions to antidiabetic actions
from the other PPARs and their ligands are
unknown, as is the ability of PPARγ to inter-
act with peroxisome proliferators or other
environmental agents (80).
We draw three major conclusions from
this review. First, epidemiologic evidence
indicates a weak association between low
(ppt) concentrations of TCDD in serum lipid
and diabetes. Although the RR is small, the
prevalence of diabetes in Western society and
the ubiquity of DLCs suggest that even a
small increased risk of diabetes among suscep-
tible members of society would have public
health signiﬁcance. Second, we propose bio-
logic plausibility for a link between DLCs
and diabetes through interaction between Ah
receptor and PPARγ-mediated signaling path-
ways. Finally, peroxisome proliferation by
phenoxy herbicides may explain the apparent
contrast in effects of TCDD on highly
exposed industrial workers. We believe that
exploration of the interaction between Ah
receptor and PPAR signaling will be a fruitful
area for future research.
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